Cancer: Designer antiandrogens join the race against drug resistance

  1. Jatinder S Josan  Is a corresponding author
  2. John A Katzenellenbogen  Is a corresponding author
  1. University of Illinois at Urbana-Champaign, United States

In Lewis Carroll's Through the Looking-Glass, the Red Queen reveals to Alice that in her world ‘it takes all the running you can do, to keep in the same place. If you want to get somewhere else, you must run at least twice as fast as that!’. The predicament in prostate cancer is much the same: researchers and clinicians alike are forced to keep running merely to stay still, because the receptors targeted by prostate cancer drugs are continually undergoing mutations that prevent the drugs from working. Now, in eLife, Minna Balbas, Charles Sawyers and their colleagues at the Memorial Sloan-Kettering Cancer Center and the University of Chicago may have found a way to run twice as fast, by using a novel approach to redesign drugs to restore their clinical efficacy (Balbas et al., 2013).

Prostate cancer is driven largely by male hormones, otherwise known as androgens, acting through the androgen receptor (Figure 1A). Consequently, the majority of cases can be treated by depriving the tumors of androgens: this is achieved by suppressing the production of androgens and by administering antiandrogen drugs, such as flutamide and bicalutamide (Figure 1B). By binding to the same site on the receptor as endogenous androgens, these drugs—which are known as receptor antagonists—prevent the hormones from activating the receptor. With time, however—sometimes only a matter of months—the cancer returns in a form resistant to these therapies, termed ‘castration-resistant prostate cancer’. Resistance can arise through various means (Knudsen and Scher, 2009), but many cases result from mutation of the androgen receptor (e.g., Veldscholte et al., 1990; Hara et al., 2003; Figure 1C). This is because the gene encoding the androgen receptor is on the X chromosome, which means that men have only a single copy and therefore any change in the gene must be expressed in the protein.

Addressing the development of resistance to antiandrogen drugs is an important challenge in prostate cancer research.

(A) Prostate cancer is driven by male hormones (androgens) such as dihydrotestosterone (DHT) binding to the androgen receptor (AR). This enables proteins called coactivators to bind to the receptor, which can then act as a nuclear transcription factor, leading to growth of the tumor. (B) Conventional prostate cancer treatments, such as bicalutamide (Bic), are androgen receptor antagonists. By binding to the same site on the receptor as endogenous androgens, they prevent activation of the receptor. (C) Antiandrogen drugs fail when mutations in the androgen receptor change its structure in a way that allows the receptor to be activated, even when the drug is bound to it: this leads to the emergence of drug-resistant forms of prostate cancer (CRPC). The yellow star denotes the W741C mutation that makes the receptor resistant to Bic. (D) Enzalutamide (Enz) is a potent drug for treating prostate cancer, but its efficacy is also threatened by the emergence of drug resistance. (E) To tackle this problem, Balbas et al. took a prospective approach: They identified a new mutation (cyan star, F876L) that completely removed the therapeutic efficacy of Enz. (F) Then, guided by a model of the structure of the drug–receptor complex, they developed an alternative form of Enz (DR) that prevents activation of both wild-type and mutant receptors. Treatment with DR led to a marked reduction in prostate cancer cell proliferation and tumor growth, even for the L876 mutant that was resistant to Enz. Ligands are highlighted in green when the androgen receptor complex is activated and in red-mauve when the complex is inactivated.

Over the past few years, Sawyers and collaborators have brought a number of more effective antiandrogens to the clinic, most notably enzalutamide (Enz) (Figure 1D). This drug binds to the androgen receptor with high affinity and effects a more complete blockade of receptor signaling than earlier drugs, providing significant survival benefit in advanced castration-resistant prostate cancer (Scher et al., 2012). Nevertheless, cases of resistance to Enz are being encountered in the clinic (Efstathiou et al., 2012; Richards et al., 2012).

Balbas et al. dived directly into the drug resistance conundrum by using structural modeling to guide the development of new Enz analogues that are able to inhibit the mutant androgen receptors. They developed a system to monitor androgen receptor activity using flow cytometry, and then used random mutagenesis to produce mutant forms of the receptor. Treating cells containing these receptors with Enz, and repeatedly selecting those that survived, led to the emergence of one particular mutation—known as F876L—in which Enz activated the receptor (that is, Enz acted as an agonist). Enz stimulated the growth of cells containing this receptor, both in vitro and in tumor tissue grafts introduced into mice (xenografts) (Figure 1E). Even without prior mutagenesis, this same Enz-resistant genotype (and a closely related mutation called F876I) emerged spontaneously both in cells and in xenografts grown in the presence of Enz. Mutant drug-resistant forms of therapeutic targets typically no longer bind the drug that should inhibit them—a loss of function; by contrast, the mutant androgen receptor binds Enz six times more effectively than the wild-type receptor does, and responds to it as an agonist—a double gain of function.

So, what can be done to restore ‘lack of function’—that is, antagonism—to drugs faced with the F876L mutant receptor? Here, the use of molecular modeling to simulate receptor–drug complexes can provide valuable guidance. Balbas, Sawyers and co-workers modeled androgen receptors complexed with bicalutamide and related analogues, and evaluated the orientation of the drug within the complex. The results were instructive, revealing that Enz binds in an orientation different from that of bicalutamide (Figure 1B vs Figure 1D). The alternative mode of receptor antagonism favored by Enz has been observed before in the estrogen receptor, where it was termed ‘indirect antagonism’ (Shiau et al., 2002; Zheng et al., 2012). When Enz binds to the wild-type androgen receptor, an interaction between the drug and the F876 residue in the receptor appears to angle Enz in such a way as to block coactivator binding. However, modeling suggests that when Enz binds to the L876 mutant receptor, this interaction no longer occurs, and the receptor instead adopts a conformation in which Enz functions as an agonist (Figure 1E).

So, might it be possible to alter drug interaction with the L876 mutant receptor to restore antagonism? The investigators used their model of Enz bound to the L876 androgen receptor to guide modifications of the Enz structure, enlarging it in a specific direction until they identified an Enz analogue that induced an antagonist conformation in the L876 mutant (Figure 1F). Gratifyingly, these larger analogues, notably one known as DR103, proved to be effective antagonists of mutant as well as wild-type androgen receptors in both cellular and xenograft prostate cancer models.

It would be reassuring to have these computational models verified by crystallographic studies, although obtaining androgen receptor structures with antagonists has thus far proven difficult. Moreover, some open questions remain: are the F876L/I androgen receptor mutations clinically relevant, appearing in patients when resistance to Enz develops? Can the success of this approach be further validated by applying the same principle to bicalutamide, and designing analogues that restore antagonist efficacy against bicalutamide-resistant mutants? Will L876 mutant tumors treated with DR103 develop further androgen receptor mutations that then defeat the antagonism of these new analogues, requiring another lap in the Red Queen's race?

Thus, it remains to be determined whether this preemptive design of antiandrogens active on wild-type and prospective androgen receptor mutants will improve long-term survival in advanced castration-resistant prostate cancer. Finally, although genetic analysis has revealed a strong association between point mutations and resistance to antiandrogens, androgen receptor mutation does not account for most cases of castration-resistant prostate cancer (Taplin et al., 2003; Taplin and Balk, 2004). Thus, the potential utility of this approach rests on the development of suitable biomarkers and the identification of patients who could benefit from therapy directed to their particular androgen receptor genotype.

Prostate cancer is poised to enter a new era of personalized health care. The next breakthroughs in therapeutics will occur with an in-depth mechanistic understanding of the events underlying disease progression and the development of resistance. The approach taken by Balbas et al. provides a compelling paradigm for improving the durability of therapies, by strategically redesigning drugs to compensate for resistance arising from mutations in their targets. The same approach could also used to extend the effectiveness of other targeted therapies before resistance arises.


    1. Hara T
    2. Miyazaki J
    3. Araki H
    4. Yamaoka M
    5. Kanzaki N
    6. Kusaka M
    et al. (2003)
    Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome
    Cancer Res 63:149–153.

Article and author information

Author details

  1. Jatinder S Josan

    Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, United States
    For correspondence
    Competing interests
    The authors declare that no competing interests exist.
  2. John A Katzenellenbogen

    the Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, United States
    For correspondence
    Competing interests
    The authors declare that no competing interests exist.

Publication history

  1. Version of Record published: April 9, 2013 (version 1)


© 2013, Josan and Katzenellenbogen

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.


  • 652
    Page views
  • 71
  • 7

Article citation count generated by polling the highest count across the following sources: Scopus, Crossref, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jatinder S Josan
  2. John A Katzenellenbogen
Cancer: Designer antiandrogens join the race against drug resistance
eLife 2:e00692.
  1. Further reading

Further reading

    1. Cancer Biology
    Qiaomu Tian, Peng Zhang ... Anita S Chong
    Research Article Updated

    Pancreatic cancer is the seventh leading cause of cancer-related death worldwide, and despite advancements in disease management, the 5 -year survival rate stands at only 12%. Triptolides have potent anti-tumor activity against different types of cancers, including pancreatic cancer, however poor solubility and toxicity limit their translation into clinical use. We synthesized a novel pro-drug of triptolide, (E)–19-[(1’-benzoyloxy-1’-phenyl)-methylidene]-Triptolide (CK21), which was formulated into an emulsion for in vitro and in vivo testing in rats and mice, and used human pancreatic cancer cell lines and patient-derived pancreatic tumor organoids. A time-course transcriptomic profiling of tumor organoids treated with CK21 in vitro was conducted to define its mechanism of action, as well as transcriptomic profiling at a single time point post-CK21 administration in vivo. Intravenous administration of emulsified CK21 resulted in the stable release of triptolide, and potent anti-proliferative effects on human pancreatic cancer cell lines and patient-derived pancreatic tumor organoids in vitro, and with minimal toxicity in vivo. Time course transcriptomic profiling of tumor organoids treated with CK21 in vitro revealed <10 differentially expressed genes (DEGs) at 3 hr and ~8,000 DEGs at 12 hr. Overall inhibition of general RNA transcription was observed, and Ingenuity pathway analysis together with functional cellular assays confirmed inhibition of the NF-κB pathway, increased oxidative phosphorylation and mitochondrial dysfunction, leading ultimately to increased reactive oxygen species (ROS) production, reduced B-cell-lymphoma protein 2 (BCL2) expression, and mitochondrial-mediated tumor cell apoptosis. Thus, CK21 is a novel pro-drug of triptolide that exerts potent anti-proliferative effects on human pancreatic tumors by inhibiting the NF-κB pathway, leading ultimately to mitochondrial-mediated tumor cell apoptosis.

    1. Biochemistry and Chemical Biology
    2. Cancer Biology
    Pengfei Guo, Rebecca C. Lim ... Hui Zhang
    Research Article

    The Polycomb Repressive Complex 2 (PRC2) methylates H3K27 to regulate development and cell fate by transcriptional silencing. Alteration of PRC2 is associated with various cancers. Here, we show that mouse Kdm1a deletion causes dramatic reduction of PRC2 proteins, whereas mouse null mutation of L3mbtl3 or Dcaf5 results in PRC2 accumulation and increased H3K27 trimethylation. The catalytic subunit of PRC2, EZH2, is methylated at lysine 20 (K20), promoting EZH2 proteolysis by L3MBTL3 and the CLR4DCAF5 ubiquitin ligase. KDM1A (LSD1) demethylates the methylated K20 to stabilize EZH2. K20 methylation is inhibited by AKT-mediated phosphorylation of serine 21 in EZH2. Mouse Ezh2K20R/K20R mutants develop hepatosplenomegaly associated with high GFI1B expression, and Ezh2K20R/K20R mutant bone marrows expand hematopoietic stem cells and downstream hematopoietic populations. Our studies reveal that EZH2 is regulated by methylation-dependent proteolysis, which is negatively controlled by AKT-mediated S21 phosphorylation to establish a methylation-phosphorylation switch to control the PRC2 activity and hematopoiesis.